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Not in the genotype: can unexplained hemophilia A result from
“micro(RNA) management”?
M
icro RNAs (miRNAs), first discovered in
1993, are noncoding RNA sequences ranging
between 17 and 25 bp in length. They regu-
late genes posttranscriptionally, primarily
acting to fine-tune gene expression, although recent
research suggests that miRNAs may also serve as master
regulators depending on the context, as in neural develop-
ment and function,1 intracellular signaling pathways,2 glo-
merular function and homeostasis,3 and so on. The most
recent update of the miRBase online database (http://
mirbase.org/, updated March 12, 2018) lists 1917 annotated
hairpin precursors and 2654 mature sequences of miRNAs
found in the human genome4 that are believed to regulate
over 60% of human protein coding genes. miRNA biogene-
sis follows multiple well-coordinated steps involving two
RNaseIII enzymes: Drosha, which initiates processing of the
long primary transcript into pre-miRNA in the nucleus, and
Dicer, which cleaves the pre-miRNA subsequently exported
into the cytoplasm, liberating the mature miRNA duplex.5
Together with Argonaute proteins, the mature miRNA forms
the RNA-induced silencing complex and targets messenger
RNAs (mRNAs), leading to inhibition of translation and/or
degradation of transcript.6
Given the pivotal role miRNAs play in cellular pro-
cesses such as development, differentiation, proliferation,
and apoptosis, any dysregulation of miRNAs is likely to per-
turb cellular physiology and thereby contribute to disease
development. Not surprisingly, deficiencies or excesses of
miRNAs have been linked to many human disorders,
including cancer,7 neurodegenerative disorders,8 autoim-
mune diseases,9 diabetes,10 cardiovascular diseases,11 and
so on. Furthermore, miRNAs offer great potential as diag-
nostic and prognostic biomarkers12 in addition to being
suitable targets for therapeutic intervention.13
The role of miRNAs in blood coagulation, despite their
ubiquitous involvement in most biologic processes, is still
poorly understood, but a few recent reports14–16 have sought
to broaden our horizons, especially regarding the regulation
of expression of hemostatic factors. “Clinical Manifestation of
Hemophilia A in the Absence of Mutations in the F8 Gene
That Encodes FVIII: Role of Micro RNAs” by Jankowska and
colleagues17 in this issue of TRANSFUSION is another valu-
able addition to the growing knowledge base in this field. In
this promising study, the investigators have attempted to
unravel the mechanism behind the mild and moderate clini-
cal phenotype of hemophilia A (HA) observed in two
patients, part of a small subset (<2%) of patients with HA
with no attributable causative mutation(s) in their F8 genes.
Among eight dysregulated miRNAs, they were able to identify
two, hsa-miR-374b-5p and hsa-miR-30c-5p, that were signifi-
cantly up regulated in both patients. Both miRNAs are known
to be expressed in human liver and are predicted to bind to
target sites in the 30 untranslated region (UTR) of F8 mRNA.
In vitro overexpression followed by inhibitor studies in cells
constitutively expressing factor VIII (FVIII) demonstrated a
“fine-tuning” role for these two miRNAs in regulating F8
gene expression.
As the authors acknowledge, their observation is more
hypothesis-generating than a definitive proof that the up
regulation of the two miRNAs unequivocally causes the HA
phenotype in these patients. In a recent publication, Nourse
et al.16 identified 52 specific miRNA interactions with 11 key
hemostatic associated genes including the F8 gene by using
in vitro RNA affinity purification in conjunction with next-
generation sequencing. Interestingly, neither miR-374b-5p
nor miR-30c-5p were among the many miRNAs functionally
validated to interact with the 30 UTR of the F8 gene as ana-
lyzed by transfection studies in the human hepatic cell line
HuH-7. These seemingly contradictory findings only rein-
force the extremely complex nature of miRNA-mediated
regulation of the hemostatic system that may occur at differ-
ent levels of action. The regulatory interactions could be
either direct between one or several miRNAs with the
corresponding mRNAs or indirect via miRNA targeting of
other elements such as receptors, transcription factors,
and/or other intermediate proteins.
Jankowska and colleagues17 were able to narrow down
to the two miRNAs based on three computerized prediction
algorithms. However, a relatively large number of potential
mRNA targets exist for any single miRNA. The dozens of
available online prediction tools18 rely on complementarity
of evolutionarily conserved seed regions spanning a mere
six nucleotides, resulting in a high number of false matches.
Therefore, a reliable in silico prediction search might
require the use of several different algorithms. Such predic-
tions are typically not cell specific and do not take biologic
context into account, including genetic events such as RNA
editing or alternative splicing that might affect miRNA bind-
ing to its target mRNA.19 The robustness of future studies
will depend on the development of tools that can accurately
predict the complex modulation occurring within a particu-
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Hemostasis reflects a delicate balance between pro- and
anticoagulant and profibrinolytic mechanisms, and any distur-
bance could result in either bleeding or thrombosis. The
52 functionally confirmed interactions involving 40 miRNAs
and 11 hemostatic genes identified by Nourse et al.16 included
cooperative miRNA regulation of key procoagulant (F7, F8, F11,
FGA, FGG, and KLKB1), anticoagulant (SERPINA 10, PROZ,
SERPIND 1, and SERPINC 1), and fibrinolytic (PLG) compo-
nents. Jankowska and colleagues17 carried out a methodical
genetic and clinical characterization of the two patients withHA
in terms of their procoagulant parameters, but seemed to have
overlooked the anticoagulant and fibrinolytic components in
their analysis. Any comprehensive follow-up study in the future
is unlikely to be complete without the inclusion of these param-
eters. In addition, the data presented by Jankowska and col-
leagues in the current report and the intriguing lack of overlap
with some of the key findings from their previously published
work20 raises important questions about the likely influence of
ethnic and/or geographic factors on miRNA profiles and their
regulation of FVIII gene expression.
Unlike in cancer,21 little is known about the associations
between miRNA single-nucleotide polymorphisms (SNPs) and
hemostasis or thrombosis. A recent report22 based solely
on in silico prediction suggested that an SNP (c.8728 A > G
rs1050705, position 1672 of the mRNA) found in the 30 UTR of
the F8 gene in patients with HA likely affects putative miRNA
binding and acts as a potential modifier of the HA phenotype.
Further analysis of a larger subset of patients with HA with
more reliable in silico prediction tools backed up by functional
assays could shed more light on the miRNA-mediated regula-
tion of coagulation and thrombosis.
In conclusion, the report by Jankowska and col-
leagues17 lays a solid groundwork for more robust investiga-
tions in the future into the complex regulation of the
hemostatic system by miRNAs in general and the finely bal-
anced expression of the F8 gene in particular. More com-
prehensive studies are likely to fill in the knowledge gaps
and address some of the critical issues discussed here.
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